Serum Uric Acid in Adolescents With Primary Headache: A Case-Control Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Primary Headache Disorders. Basic parameters: 12 years — 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Association Between Serum Uric Acid Levels and Primary Headaches in Adolescents: A Case-Control Study
Overview
This observational, case-control study will evaluate differences in serum uric acid and related hematologic and biochemical parameters between adolescents (12-18 years) with primary headache and age-/sex-matched controls without recurrent headaches or chronic medical/psychiatric disorders. Cases will meet International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria verified by a pediatric neurologist after comprehensive clinical assessment. The study will also collect sociodemographic data and anthropometrics to calculate BMI. Primary outcome is the between-group difference in serum uric acid levels at enrollment. Secondary outcomes include group differences in ferritin, creatinine, BUN, complete blood count indices (Hb, WBC, neutrophils, lymphocytes, platelets, MPV), and BMI.
Primary outcome measures
- Serum uric acid level (mg/dL) - between-group difference (Cases vs Controls) [Time frame: At enrollment (single draw)]
Secondary outcome measures (9)
- Serum Ferritin level (ug/L) [Time frame: At enrollment (single draw)]
- Serum Creatinine level(mg/dL) [Time frame: At enrollment (single draw)]
- Serum BUN level (mg/dL) [Time frame: At enrollment (single draw)]
- Hemoglobin (Hb) [Time frame: At enrollment (single draw)]
- White blood cell count (WBC) [Time frame: At enrollment (single draw)]
- Neutrophil count [Time frame: At enrollment (single draw)]
- Lymphocyte count [Time frame: At enrollment (single draw)]
- Platelet count [Time frame: At enrollment (single draw)]
- Mean platelet volume (MPV) [Time frame: At enrollment (single draw)]
Eligibility criteria
Inclusion criteria
- Inclusion Criteria (Cases):
Adolescents aged 12-18 years presenting to pediatric neurology outpatient clinics
Diagnosis of primary headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) (e.g., 1.1, 1.2, etc.)
Diagnosis confirmed by a pediatric neurologist following a comprehensive clinical evaluation
Sufficient cognitive ability to understand and complete study instruments
- Inclusion Criteria (Controls):
Adolescents aged 12-18 years presenting to general pediatric outpatient clinics
No history of recurrent headaches
No chronic medical or psychiatric disorders
Matched with the case group for age and sex
Exclusion criteria
- History of neurological disorders other than primary headache
- Previously diagnosed psychiatric conditions
- Autoimmune diseases, chronic infections, severe cardiac failure, metabolic or inflammatory disorders, obesity, or significant hepatic or renal impairment
- Regular use of psychotropic medications or a history of polycythemia
- Use of drugs known to affect uric acid metabolism within 2-4 weeks prior to enrollment
- Cognitive or developmental disabilities limiting the ability to understand or complete study instruments
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07460830 · 2025002